Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors [PDF]
Molecules, 2016 The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/
Milan Remko, Anna Remková, Ria Broer
doaj +8 more sources
Discovery and development of Factor Xa inhibitors (2015–2022) [PDF]
Frontiers in Pharmacology, 2023 As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT).
Wei Zheng +5 more
doaj +3 more sources
Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors [PDF]
Nature Communications, 2017 A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events.
Daniël Verhoef +6 more
doaj +4 more sources
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation [PDF]
Journal of Neurology, 2023 Background Oral Factor Xa inhibitors for the prevention of stroke in atrial fibrillation require dose adjustment based on certain clinical criteria, but the off-label use of the reduced doses is common. Methods
Fröhlich, Kilian +9 more
core +3 more sources
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. [PDF]
Cochrane Database Syst Rev, 2023 BACKGROUND Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly of the leg. It occurs in approximately one in 1000 people.
Wang X +11 more
europepmc +2 more sources
Structural Basis for Inhibition Promiscuity of Dual Specific Thrombin and Factor Xa Blood Coagulation Inhibitors [PDF]
, 2001 Background: A major current focus of pharmaceutical research is the development of selective inhibitors of the blood coagulation enzymes thrombin or factor Xa to be used as orally bioavailable anticoagulant drugs in thromboembolic disorders and in the ...
Bauer, Margit +8 more
core +3 more sources
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study [PDF]
Research and Practice in Thrombosis and Haemostasis, 2021 Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA).
Eva N. Hamulyák +18 more
doaj +2 more sources
Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data? [PDF]
Advances in Hematology, 2011 The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative.
Ali Zalpour +4 more
doaj +4 more sources
Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background Important disparities in the treatment and outcomes of women and men with atrial fibrillation (AF) are well recognized. Whether introduction of direct oral anticoagulants has reduced disparities in treatment is uncertain.
Kuan Ken Lee +14 more
doaj +3 more sources
Andexanet alfa - what we know about this promising drug [PDF]
Journal of Education, Health and Sport, 2023 Introduction and purpose. Andexanet alfa (AA) is a recombinant modified version of human activated factor X. It is used as an antidote for apixsaban and rivaroxaban when reversal of anticoagulation due to life-threatening or uncontrolled bleeding is ...
Natalia Ilnicka +4 more
doaj +3 more sources